Merck & Co., Inc. Quarterly Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Merck & Co., Inc. (NYSE:MRK) will unveil its latest earnings on Friday, July 29, 2011. Merck & Co. Inc. is a global research-driven company that develops and manufactures a range of innovative pharmaceutical products to improve human and animal health.

Merck & Co., Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 95 cents per share, a rise of 10.5% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 93 cents. For the year, analysts are projecting profit of $3.74 per share, a rise of 9.4% from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 8 cents, reporting net income of 92 cents per share against a mean estimate of profit of 84 cents per share.

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>

Wall St. Revenue Expectations: On average, analysts predict $11.78 billion in revenue this quarter, a rise of 3.8% from the year ago quarter. Analysts are forecasting total revenue of $47.13 billion for the year, a rise of 2.5% from last year’s revenue of $45.99 billion.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, none rating it as a sell and six rating it as a hold.

Key Stats:

Revenue has risen the past four quarters. Revenue increased 1.4% to $11.58 billion in first quarter. The figure rose 19.8% in the fourth quarter of the last fiscal year from the year earlier, climbed 83.9% in the third quarter of the last fiscal year from the year-ago quarter and 92.3% in the second quarter of the last fiscal year.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), GlaxoSmithKline plc (NYSE:GSK), Sanofi-Aventis SA (NYSE:SNY), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), and Novartis AG (NYSE:NVS).

Stock Price Performance: During June 24, 2011 to July 25, 2011, the stock price had risen $1.34 (3.9%) from $34.55 to $35.89. The stock price saw one of its best stretches over the last year between April 21, 2011 and May 4, 2011 when shares rose for nine-straight days, rising 7.4% (+$2.49) over that span. It saw one of its worst periods between May 18, 2011 and May 27, 2011 when shares fell for eight-straight days, falling 3.7% (-$1.36) over that span. Shares are up 65 cents (+1.8%) year to date.

(Source: Xignite Financials)

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>